IL5 and congenital rubella syndrome: Previously described RCTs and systematic reviews showed that blocking the inflammatory response related to the effects of IL-5 clearly had an effect on decreasing systemic and nasal eosinophilia.60, 61 However, larger studies involving eosinophilic CRS are still needed, especially to define which subgroups of patients will show better responses, in order to minimize resource waste and maximize the effects of anti-IL-5 therapy, thus defining the real role of these drugs in CRS (Table 2).